PGRN Oncology Special Interest Group

The new PGRN Oncology SIG has identified the following three areas of interest. Each area has a subcommittee (~5 individuals) who will help coordinate the activities within that domain. Below are brief descriptions and 1- and 5-year plans for each subcommittee:


R. Stephanie Huang, PhD
University of Minnesota, USA
Group Lead

1) Collaborative Cancer PGx Research (CPR, Lead: Britt Drogemoller) Leadership Team: Eileen Dolan, Deana Kroetz, Gabriele Stocco, and David Twesigomwe


The purpose of CPR subcommittee is to facilitate opportunities to i) enhance collaborative research among members of the PGRN Oncology SIG and ii) generate high impact research outputs (e.g. publications, grants) for members of this group.

Our 1-year goals are to:

  1. Create a repository of previously published data (e.g. GWAS summary statistics)
  2. Create a searchable database of PGx oncology cohorts that are available through the SIG to facilitate collaboration between researchers focusing on similar PGx traits, which will results in successful PGRN grant(s)
  3. Explore opportunities to integrate PGx research into already existing cancer genetics projects (e.g. CONFLUENCE project)

Our 5-year goals are to:

  1. Publish articles from research performed using data housed in the repository
  2. Generate collaborative research outputs that are enabled through the use of the searchable database. This includes submission of grants to major funding agencies (e.g. NIH), which include pilot data generated using funds from successful PGRN grant(s).
  3. Demonstrate how PGx can be integrated into large-scale cancer projects and identify additional large-scale resources where PGx can be integrated



Britt Drögemöller, PhD
University of Manitoba, Canada
Lead, Collaborative Cancer PGx Research

2) Clinical PGx Implementation (CPI, Lead: Cyrine Haidar) Leadership Team: Cyrine Haidar, April Schultz, Amy Pasternak, Ben Kong, Max Smith, and Chakradhara Uppugunduri

The purpose of the Clinical PGx Implementation subcommittee is to i) serve as hub to connect oncology PGx practitioners and ii) to allow oncology PGx practitioners to seek and exchange implementation successes and challenges,

Our 1-year goals are to:

  1. Introduce the PGRN Onc SIG to the oncology implementers in the pharmacogenomics community
  2. Understand the current state of clinical gene/drug pair implementations at oncology sites
  3. Create a searchable database of pharmacogenomics practitioners to facilitate the discussion and exchange of oncology PGx implementation experience

Our 5-year goals are to:

  1. Publish articles highlighting unique implementation aspects at oncology PGx sites
  2. Establish a network of oncology pharmacogenomics practitioners
  3. Serve as the main forum for PGx oncology practitioners for implementation data sharing and collaboration (for example, with IGNITE)




Cyrine-Eliana Haidar, PharmD, BCPS, BCOP, FASHP
St. Jude Children's Research Hospital, USA
Lead, Clinical PGx Implementation

3) Enhancing PGx in Oncology Organizations (EPO, Lead: Dan Hertz) Leadership Team: Howard McLeod, Stuart Scott, HJ Guchelaar, Cyrine Haider, and Bryan Schneider

The purpose of the EPO subcommittee is to enhance the visibility and awareness of germline pharmacogenetics in the clinical oncology community.

Our 1-year goals are to:

  1. Introduce PGRN Onc SIG members to the NCTN groups and their PGx research efforts
  2. Propose PGx-related sessions for ASCO 2023 and 2024, and perhaps other oncology organizations (e.g., AACR, ASH, ACS, ASPHO)
  3. Understand the current state of germline PGx recommendations within clinical oncology guidelines (e.g., white paper/review writing, Endorsement of CPIC guidelines, Inclusion of PGx in germline testing recommendations)

Our 5-year goals are to:

  1. Create a consistent presence for PGx within each of the NCTN groups
  2. Increase prevalence of oncology PGx sessions and research at clinical oncology conferences
  3. Build relationships with clinical guidelines committees to enhance their inclusion of germline PGx within practice guidelines, potentially including endorsement of CPIC dosing recommendations and inclusion of PGx in germline dosing recommendations.


Dan Hertz. PharmD, PhD
University of Michigan, USA
Lead, Enhancing PGx in Oncology Organizations

If you are interested in joining the PGRN Oncology SIG, please email PGRN Office at info@pgrn.org.

PGRN awards, seminars and meetings are open to Members Only.

Join now so you can take advantage of PGRN's seminars, research in progress sessions,
tool kits and awards.




Copyright © 2020 the Pharmacogenomics Global Research Network. All Rights Reserved.

PGRN is a 501(c)3 Non-Profit Association

Follow PGRN
on Social Media

Become a Member

PGRN logo
Membership dues are vital to continue the mission and work of the PGRN. Join your colleagues today and suport the work of PGRN. 
Powered by Wild Apricot Membership Software